<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055206</url>
  </required_header>
  <id_info>
    <org_study_id>SPECT-CT</org_study_id>
    <secondary_id>20-5607</secondary_id>
    <nct_id>NCT05055206</nct_id>
  </id_info>
  <brief_title>Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers</brief_title>
  <official_title>A Feasibility Trial of Lymphatic Mapping With SPECT-CT for Evaluating Contralateral Disease in Lateralized Oropharynx Cancer Using 99m-Technetium Sulfur Colloid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see how practical it is to inject a radiotracer called&#xD;
      99m-Technetium Sulfur Colloid around the tumors for the imaging of patients with&#xD;
      oropharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate a technique called lymphatic drainage mapping. This is a technique&#xD;
      where a radiotracer (a radioactive material that can be seen with a special computed&#xD;
      tomography [CT] scanner to create 3D images) is injected into a vein around the tumour,&#xD;
      either with local anesthesia or under general anesthesia. The radiotracer that will be used&#xD;
      for the lymphatic drainage mapping is called 99m-Technetium Sulfur Colloid. Images will be&#xD;
      taken of neck to detect the movement of the radiotracer. This will allow the doctors to see&#xD;
      the drainage pattern of the lymph nodes in the neck.&#xD;
&#xD;
      The information from this study will be used to better understand the tendency for&#xD;
      oropharyngeal cancers to spread to lymph nodes. In addition, the information from this&#xD;
      clinical trial will be used in future clinical studies to help specialists identify&#xD;
      strategies to help plan treatment based on this type of imaging study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">September 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients injected with radiotracer.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients requiring general anesthetic over local anesthetic.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with images that failed radiotracer migration to either side of the neck.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients completing 30 minute scan.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients completing 3 hour scan.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with radiotracer uptake into a radiographically positive lymph node.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with injections site locations that are compliant with protocol specific map of injection locations.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average time from start to finish of injection of procedure.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with complications associated with injection.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Oropharynx Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphatic drainage mapping in patients with oropharynx cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour.&#xD;
Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SPECT-CT</intervention_name>
    <description>99m-Technetium Sulfur Colloid will be injected prior to the scan.</description>
    <arm_group_label>Lymphatic drainage mapping in patients with oropharynx cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has lateralized oropharyngeal carcinoma (tonsil or tongue base) not involving&#xD;
             midline&#xD;
&#xD;
          -  Has squamous cell carcinoma, T1-3 tumours, with no contralateral nodes on clinical&#xD;
             exam or axial imaging&#xD;
&#xD;
          -  Human papillomavirus (HPV) positive or negative&#xD;
&#xD;
          -  Patient should have normal organ function as per Investigator judgement&#xD;
&#xD;
          -  Patient is planned for definitive or adjuvant radiotherapy (RT) or chemo radiotherapy&#xD;
             (CRT) with bilateral neck RT, or surgery&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4 tumours&#xD;
&#xD;
          -  Contralateral/bilateral nodal disease or node(s) &gt; 6cm on clinical exam or axial&#xD;
             imaging or positron emission tomography (PET)&#xD;
&#xD;
          -  Primary tumour involving or crossing midline&#xD;
&#xD;
          -  Soft palate or posterior pharyngeal wall tumour subsites&#xD;
&#xD;
          -  Previous head and neck cancer&#xD;
&#xD;
          -  Previous radiotherapy (RT) to the head and neck&#xD;
&#xD;
          -  Previous neck dissection&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Prior invasive malignancy (except non-melanoma skin cancer) unless disease free for 3&#xD;
             years&#xD;
&#xD;
          -  Prior radiotracer allergy&#xD;
&#xD;
          -  Multiple primary head and neck cancers&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John de Almeida, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John de Almeida, M.D.</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>2149</phone_ext>
    <email>John.deAlmeida@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John de Almeida, M.D.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2149</phone_ext>
    </contact>
    <investigator>
      <last_name>John de Almeida, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphatic Drainage Mapping</keyword>
  <keyword>99m-Technetium Sulfur Colloid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

